Literature DB >> 7947197

Epidemiology of solar keratoses.

C A Frost1, A C Green.   

Abstract

Solar keratoses (SKs) or actinic keratoses are common dysplastic epidermal lesions which occur in pale-skinned individuals who are chronically exposed to intense sunlight. Together with basal cell carcinomas and squamous cell carcinomas, they constitute a major public health problem in such individuals. Reported SK prevalence rates range from 11 to 25% in various northern hemisphere populations, and amongst Australian adults the range is from 40 to 60%. In the only study to date reporting SK incidence data, 60% of subjects aged 40 years and over with SKs at baseline developed new lesions during 12 months of follow-up, compared with only 19% of those who were lesion-free on the first examination. Because existing epidemiological data on SKs are sparse, very little is known of their natural history, their role in carcinogenesis, or their preventability. In this review, current knowledge about the aetiology, diagnosis, and occurrence of SKs is discussed, as is the need for prospective studies in unselected communities. With accurate baseline data, public health authorities should be in a better position to determine the best preventive strategies, and to evaluate the effectiveness of these programmes.

Entities:  

Mesh:

Year:  1994        PMID: 7947197     DOI: 10.1111/j.1365-2133.1994.tb08544.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  40 in total

1.  Safety and Efficacy of Multiple 16-week Courses of Topical Imiquimod for the Treatment of Large Areas of Skin Involved with Actinic Keratoses.

Authors:  James Q Del Rosso; Howard Sofen; Barry Leshin; Tc Meng; James Kulp; Sharon Levy
Journal:  J Clin Aesthet Dermatol       Date:  2009-04

2.  Developing an interactive web-based learning program on skin cancer: the learning experiences of clinical educators.

Authors:  Waqas R Shaikh; Alan Geller; Gwen Alexander; Maryam M Asgari; Gunther J Chanange; Stephen Dusza; Melody J Eide; Suzanne W Fletcher; Jacqueline M Goulart; Allan C Halpern; Shoshana Landow; Ashfaq A Marghoob; Elizabeth A Quigley; Martin A Weinstock
Journal:  J Cancer Educ       Date:  2012-12       Impact factor: 2.037

3.  Tolerability of Ingenol Mebutate Gel, 0.05%, for Treating Patients with Actinic Keratosis on the Scalp in a Community Dermatology Practice.

Authors:  Miriam S Bettencourt
Journal:  J Clin Aesthet Dermatol       Date:  2016-03-01

Review 4.  Actinic keratoses. Differential diagnosis and treatment.

Authors:  J W Barnaby; A R Styles; C J Cockerell
Journal:  Drugs Aging       Date:  1997-09       Impact factor: 3.923

5.  Predictors for cutaneous basal- and squamous-cell carcinoma among actinically damaged adults.

Authors:  J A Foote; R B Harris; A R Giuliano; D J Roe; T E Moon; B Cartmel; D S Alberts
Journal:  Int J Cancer       Date:  2001-01-20       Impact factor: 7.396

6.  Three-day Field Treatment with Ingenol Disoxate (LEO 43204) for Actinic Keratosis: A Phase II Trial.

Authors:  Daniel M Siegel; Stephen Tyring; Walter K Nahm; Marie Louise Østerdal; Astrid H Petersen; Brian Berman
Journal:  J Clin Aesthet Dermatol       Date:  2017-12-01

7.  Validity and Reliability of the Dutch Adaptation of the Actinic Keratosis Quality of Life Questionnaire (AKQoL).

Authors:  Kelly Vis; Rick Waalboer-Spuij; Dyon G C T M Snels; Loes M Hollestein
Journal:  Dermatology       Date:  2018-06-15       Impact factor: 5.366

Review 8.  Molecular cancer prevention: Current status and future directions.

Authors:  Karen Colbert Maresso; Kenneth Y Tsai; Powel H Brown; Eva Szabo; Scott Lippman; Ernest T Hawk
Journal:  CA Cancer J Clin       Date:  2015-08-18       Impact factor: 508.702

Review 9.  [Actinic keratoses].

Authors:  P Babilas; M Landthaler; R-M Szeimies
Journal:  Hautarzt       Date:  2003-06       Impact factor: 0.751

Review 10.  Health economic evaluation of non-melanoma skin cancer and actinic keratosis.

Authors:  Mitchell K Higashi; David L Veenstra; Paul C Langley
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.